(Q33375798)

English

High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). (English)

1 reference

Europe PubMed Central

26 July 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

Wolfgang Hiddemann

12

object named as

Wolfgang Hiddemann

1 reference

Europe PubMed Central

26 July 2017

Martin Dreyling

13

object named as

Martin Dreyling

1 reference

Europe PubMed Central

26 July 2017

Michael Unterhalt

11

object named as

Michael Unterhalt

1 reference

Europe PubMed Central

26 July 2017

author name string

Rudolf Weide

1

1 reference

Europe PubMed Central

26 July 2017

Georg Hess

2

1 reference

Europe PubMed Central

26 July 2017

Hubert Köppler

3

1 reference

Europe PubMed Central

26 July 2017

Jochen Heymanns

4

1 reference

Europe PubMed Central

26 July 2017

Jörg Thomalla

5

1 reference

Europe PubMed Central

26 July 2017

Ali Aldaoud

6

1 reference

Europe PubMed Central

26 July 2017

Christoph Losem

7

1 reference

Europe PubMed Central

26 July 2017

Stefan Schmitz

8

1 reference

Europe PubMed Central

26 July 2017

Ursula Haak

9

1 reference

Europe PubMed Central

26 July 2017

Christoph Huber

10

1 reference

Europe PubMed Central

26 July 2017

German Low Grade Lymphoma Study Group

14

1 reference

Europe PubMed Central

26 July 2017

publication date

1 July 2007

1 reference

Europe PubMed Central

26 July 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

26 July 2017

48

1 reference

Europe PubMed Central

26 July 2017

1299-1306

1 reference

Europe PubMed Central

26 July 2017

7

1 reference

Europe PubMed Central

26 July 2017

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

https://api.crossref.org/works/10.1080%2F10428190701361828

21 January 2018

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190701361828

21 January 2018

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

1 reference

https://api.crossref.org/works/10.1080%2F10428190701361828

21 January 2018

High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas

1 reference

https://api.crossref.org/works/10.1080%2F10428190701361828

21 January 2018

Bendamustine mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas

1 reference

https://api.crossref.org/works/10.1080%2F10428190701361828

21 January 2018

Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study

1 reference

https://api.crossref.org/works/10.1080%2F10428190701361828

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701361828

21 January 2018

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1080%2F10428190701361828

21 January 2018

Identifiers

10.1080/10428190701361828

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33375798&oldid=2092777207"